共查询到20条相似文献,搜索用时 62 毫秒
1.
2.
3.
Siriluk Ratanabunyong Dr. Niran Aeksiri Dr. Saeko Yanaka Dr. Maho Yagi-Utsumi Dr. Koichi Kato Dr. Kiattawee Choowongkomon Dr. Supa Hannongbua 《Chembiochem : a European journal of chemical biology》2021,22(5):915-923
HIV-1 RT is a necessary enzyme for retroviral replication, which is the main target for antiviral therapy against AIDS. Effective anti-HIV-1 RT drugs are divided into two groups; nucleoside inhibitors (NRTI) and non-nucleoside inhibitors (NNRTI), which inhibit DNA polymerase. In this study, new DNA aptamers were isolated as anti-HIV-1 RT inhibitors. The selected DNA aptamer (WT62) presented with high affinity and inhibition against wild-type (WT) HIV-1 RT and gave a KD value of 75.10±0.29 nM and an IC50 value of 84.81±8.54 nM. Moreover, WT62 decreased the DNA polymerase function of K103 N/Y181 C double mutant (KY) HIV-1 RT by around 80 %. Furthermore, the ITC results showed that this aptamer has small binding enthalpies with both WT and KY HIV-1 RTs through which the complex might form a hydrophobic interaction or noncovalent bonding. The NMR result also suggested that the WT62 aptamer could bind with both WT and KY mutant HIV-1 RTs at the connection domain. 相似文献
4.
5.
6.
7.
Construction of an enzymatically active ribonuclease H domain of human immunodeficiency virus type 1 reverse transcriptase 总被引:1,自引:0,他引:1
Stahl Stephen J.; Kaufman Joshua D.; Vikic-Topic Smiljka; Crouch Robert J.; Wingfield Paul T. 《Protein engineering, design & selection : PEDS》1994,7(9):1103-1108
8.
9.
Design,Synthesis, and Biological Evaluation of 1,3‐Diarylpropenones as Dual Inhibitors of HIV‐1 Reverse Transcriptase 下载免费PDF全文
Dr. Rita Meleddu Dr. Valeria Cannas Dr. Simona Distinto Dr. Giorgia Sarais Dr. Claudia Del Vecchio Dr. Francesca Esposito Dr. Giulia Bianco Dr. Angela Corona Dr. Filippo Cottiglia Prof. Stefano Alcaro Prof. Cristina Parolin Dr. Anna Artese Dr. Daniela Scalise Prof. Massimo Fresta Dr. Antonella Arridu Dr. Francesco Ortuso Prof. Elias Maccioni Prof. Enzo Tramontano 《ChemMedChem》2014,9(8):1869-1879
10.
Anna Rozina Andrey Anisenko Tatiana Kikhai Maria Silkina Marina Gottikh 《International journal of molecular sciences》2022,23(20)
RNA viruses, in pursuit of genome miniaturization, tend to employ cellular proteins to facilitate their replication. HIV-1, one of the most well-studied retroviruses, is not an exception. There is numerous evidence that the exploitation of cellular machinery relies on nucleic acid-protein and protein-protein interactions. Apart from Vpr, Vif, and Nef proteins that are known to regulate cellular functioning via interaction with cell components, another viral protein, integrase, appears to be crucial for proper virus-cell dialog at different stages of the viral life cycle. The goal of this review is to summarize and systematize existing data on known cellular partners of HIV-1 integrase and their role in the HIV-1 life cycle. 相似文献
11.
12.
Sayuri Sakuragi Osamu Kotani Masaru Yokoyama Tatsuo Shioda Hironori Sato Jun-ichi Sakuragi 《International journal of molecular sciences》2021,22(7)
Human immunodeficiency virus type 1 (HIV-1) uptakes homo-dimerized viral RNA genome into its own particle. A cis-acting viral RNA segment responsible for this event, termed packaging signal (psi), is located at the 5′-end of the viral genome. Although the psi segment exhibits nucleotide variation in nature, its effects on the psi function largely remain unknown. Here we show that a psi sequence from an HIV-1 regional variant, subtype D, has a lower packaging ability compared with that from another regional variant, HIV-1 subtype B, despite maintaining similar genome dimerization activities. A series of molecular genetic investigations narrowed down the responsible element of the selective attenuation to the two sequential nucleotides at positions 226 and 227 in the psi segment. Molecular dynamics simulations predicted that the dinucleotide substitution alters structural dynamics, fold, and hydrogen-bond networks primarily of the psi-SL2 element that contains the binding interface of viral nucleocapsid protein for the genome packaging. In contrast, such structural changes were minimal within the SL1 element involved in genome dimerization. These results suggest that the psi 226/227 dinucleotide pair functions as a cis-acting regulator to control the psi structure to selectively tune the efficiency of packaging, but not dimerization of highly variable HIV-1 genomes. 相似文献
13.
HIV-1 integrase (IN) is one of three essential enzymes for viral replication, and is a focus of ardent antiretroviral drug discovery and development efforts. Diligent research has led to the development of the strand-transfer-specific chemical class of IN inhibitors, with two compounds from this group, raltegravir and elvitegravir, advancing the farthest in the US Food and Drug Administration (FDA) approval process for any IN inhibitor discovered thus far. Raltegravir, developed by Merck & Co., has been approved by the FDA for HIV-1 therapy, whereas elvitegravir, developed by Gilead Sciences and Japan Tobacco, has reached phase?III clinical trials. Although this is an undoubted success for the HIV-1 IN drug discovery field, the emergence of HIV-1 IN strand-transfer-specific drug-resistant viral strains upon clinical use of these compounds is expected. Furthermore, the problem of strand-transfer-specific IN drug resistance will be exacerbated by the development of cross-resistant viral strains due to an overlapping binding orientation at the IN active site and an equivalent inhibitory mechanism for the two compounds. This inevitability will result in no available IN-targeted therapeutic options for HIV-1 treatment-experienced patients. The development of allosterically targeted IN inhibitors presents an extremely advantageous approach for the discovery of compounds effective against IN strand-transfer drug-resistant viral strains, and would likely show synergy with all available FDA-approved antiretroviral HIV-1 therapeutics, including the IN strand-transfer-specific compounds. Herein we review the concept of allosteric IN inhibition, and the small molecules that have been investigated to bind non-active-site regions to inhibit IN function. 相似文献
14.
Dietz J Koch J Kaur A Raja C Stein S Grez M Pustowka A Mensch S Ferner J Möller L Bannert N Tampé R Divita G Mély Y Schwalbe H Dietrich U 《ChemMedChem》2008,3(5):749-755
The interaction of the nucleocapsid NCp7 of the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein with the RNA packaging signal Psi ensures specific encapsidation of the dimeric full length viral genome into nascent virus particles. Being an essential step in the HIV-1 replication cycle, specific genome encapsidation represents a promising target for therapeutic intervention. We previously selected peptides binding to HIV-1 Psi-RNA or stem loops (SL) thereof by phage display. Herein, we describe synthesis of peptide variants of the consensus HWWPWW motif on membrane supports to optimize Psi-RNA binding. The optimized peptide, psi-pepB, was characterized in detail with respect to its conformation and binding properties for the SL3 of the Psi packaging signal by NMR and tryptophan fluorescence quenching. Functional analysis revealed that psi-pepB caused a strong reduction of virus release by infected cells as monitored by reduced transduction efficiencies, capsid p24 antigen levels, and electron microscopy. Thus, this peptide shows antiviral activity and could serve as a lead compound to develop new drugs targeting HIV-1. 相似文献
15.
16.
17.
The replication cycle of human immunodeficiency virus type 1 (HIV-1) is a complex multistep process that depends on both viral and host cell factors. The nuclear protein lens epithelium-derived growth factor (LEDGF/p75) is a multidomain protein, present in host cells, which plays an important role in the integration process. LEDGF/p75 not only binds HIV-1 integrase (IN) at its IN binding domain (IBD) but also contains several motifs that function in DNA and chromatin binding. The demonstrated importance of the association between IN and LEDGF/p75 in HIV-1 integration suggests the possibility that this protein-protein interaction (PPI) could be exploited as an antiviral target. We describe herein the progress to date in developing inhibitors of this promising target. 相似文献
18.
Jnos Andrs Mtyn Mohamed Mahdi Gyula Hoffka Jzsef Tzsr 《International journal of molecular sciences》2022,23(7)
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of potent novel antivirals had led to global health crises; however, emergence and approval of potent inhibitors of the viral main protease (Mpro), such as Pfizer’s newly approved nirmatrelvir, offers hope not only in the therapeutic front but also in the context of prophylaxis against the infection. By their nature, RNA viruses including human immunodeficiency virus (HIV) have inherently high mutation rates, and lessons learnt from previous and currently ongoing pandemics have taught us that these viruses can easily escape selection pressure through mutation of vital target amino acid residues in monotherapeutic settings. In this paper, we review nirmatrelvir and its binding to SARS-CoV-2 Mpro and draw a comparison to inhibitors of HIV protease that were rendered obsolete by emergence of resistance mutations, emphasizing potential pitfalls in the design of inhibitors that may be of important relevance to the long-term use of novel inhibitors against SARS-CoV-2. 相似文献
19.
20.
Probing the structure of the HIV-1 Rev trans-activator protein by functional analysis 总被引:2,自引:0,他引:2
Human immunodeficiency virus type 1 (HIV-1) encodes a trans-acting
regulatory protein, termed Rev, which is critically required for virus
replication. Rev is a sequence-specific RNA binding protein which mediates
the nuclear export of unspliced and incompletely spliced viral mRNAs
encoding the viral structural proteins. While CD and fluorescence
measurements have provided several possible structural models of Rev, all
attempts employing X-ray crystallography and NMR techniques have so far
failed to provide more accurate data. We present a new approach to validate
alternative structural models of the N-terminal region of Rev which
contains the nuclear localization/RNA binding domain. Points of contact
between structural elements in a protein were determined by introduction of
targeted amino acid substitutions and subsequent scoring of the biological
activities. Our data resulted in the suggestion of a new and more refined
model of HIV-1 Rev structure which to date has been impossible to obtain by
other means.
相似文献